Table 4.
Risk of acute coronary syndrome in relation to use of NSAID. Aspirin users are included in 'No NSAID'
PPARγ Pro12Ala | Ncases/Nnon-cases | HRa 95% CI | HRb 95% CI | |||||||
Men | NSAID | NSAID | NSAID | |||||||
NO | YES | NO | YES | NO | YES | |||||
Pro/Pro | 531/622 | 58/42 | 1.00 | - | 1.63 | 1.07–2.47 | 1.00 | - | 1.58 | 1.00–2.48 |
Pro/Ala | 156/190 | 20/14 | 0.91 | 0.75–1.17 | 1.61 | 0.79–3.25 | 0.91 | 0.70–1.17 | 1.63 | 0.79–3.37 |
Ala/Ala | 20/11 | 1/1 | 2.07 | 0.99–4.32 | 2.00 | 0.13–30.5 | 2.36 | 1.09–5.13 | 1.10 | 0.07–17.7 |
P for interaction | 0.918 | 0.670 | ||||||||
Pro/Pro | 531/622 | 58/42 | 1.00 | - | 1.63 | 1.07–2.47 | 1.00 | - | 1.58 | 1.00–2.48 |
Pro/Ala & Ala/Ala | 176/201 | 21/15 | 0.96 | 0.77–1.24 | 1.62 | 0.72–3.23 | 0.97 | 0.76–1.25 | 1.60 | 0.79–3.23 |
P for interaction | 0.958 | 0.929 | ||||||||
Women | ||||||||||
Pro/Pro | 145/505 | 36/76 | 1.00 | - | 1.52 | 0.96–2.41 | 1.00 | - | 1.37 | 0.84–2.23 |
Pro/Ala | 52/168 | 10/25 | 0.99 | 0.67–1.45 | 1.31 | 0.59–2.87 | 0.93 | 0.62–1.38 | 1.33 | 0.59–3.00 |
Ala/Ala | 2/9 | 0/6 | 0.61 | 0.12–2.97 | - | - | 0.54 | 0.11–2.71 | - | - |
P for interaction | 0.771 | 0.924 | ||||||||
Pro/Pro | 145/505 | 36/76 | 1.00 | - | 1.42 | 0.96–2.41 | 1.00 | - | 1.36 | 0.84–2.23 |
Pro/Ala & Ala/Ala | 54/177 | 10/31 | 0.96 | 0.66–1.41 | 1.08 | 0.50–2.32 | 0.90 | 0.61–1.34 | 1.14 | 0.52–2.51 |
P for interaction | 0.517 | 0.875 |
a) crude
b) adjusted for smoking status and alcohol consumption